The most recent data from Selvita’s SEL24 to be presented at the 57th ASH Annual Meeting & Exposition

Krakow, Poland – November 25, 2015 – Selvita, the largest drug discovery company in Central and Eastern Europe, engaged in the development of breakthrough oncology therapies, announced that data from its SEL24 oncology program is scheduled to be reported at the upcoming 57th ASH Annual Meeting & Exposition, which will take place 5 – 8 December 2015, at the Orange County Convention Center, Orlando, Florida, USA.

The data presented at the conference will include the most recent results obtained by scientists from the Institute of Hematology and Transfusion Medicine for the SEL24-B489 clinical candidate, developed by Selvita, as a potentially best-in-class dual, selective inhibitor of PIM/FLT3, in hematological malignancies.

An oral presentation regarding results of the project, entitled: ”Novel Pan-PIM Kinase Inhibitor, SEL24-B489, Induces Apoptosis and Inhibits Proliferation of Diffuse Large B-Cell Lymphoma Cells through Inhibition of Protein Translation and Attenuation of Myc and NFkB Activity”, will be presented on December 7, at 3:30 PM, during the session “625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: B-cell Receptor Signaling and Resistance in Lymphoma” starting at 2:45 PM in Hall E2.

Second oral presentation of SEL24-B489, entitled: “Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Classical Hodgkin Lymphoma”, will take place on December 7, at 5:00 PM, during the session ”625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Immune Modulation and Microenvironment in Lymphoma” starting 4:30 PM in Hall E2.

Additional results will be presented also during a poster presentation, entitled: “Activity of PIM Kinases in Chronic Lymphocytic Leukemia Modulates Tumor Cell Survival and Stromal Interactions through a Pleiotropic Mechanism Involving Modulation of CXCR4 – mTOR Pathway“, which will be presented on December 5, during the session “625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster I“, between 5:30 PM – 7:30 PM, at Hall A.

About Selvita

Selvita is a drug discovery company engaged in the research and development of breakthrough therapies in the area of oncology, as well as provision of integrated drug discovery services. Selvita was established and 2007 and currently employs over 280 people, including 88 PhDs, with extensive experience in area of life sciences. Selvita has currently several projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2016. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. Selvita offices are located in Greater Boston Area, San Francisco Area, Cambridge, UK, and Krakow, Poland. The company is listed on the Warsaw Stock Exchange (WSE:SLV).

About Institute of Hematology and Transfusion Medicine (IHT)

IHT is a reference institution for diagnosing and treatment of patients with blood malignancies. It was established in 1951 and is the main scientific center in its disciplines in Poland as well as the main reference clinical diagnostic center. Each year, about 500 new patients with hematological malignancies are seen in the Institute’s outpatient and inpatients clinics. State-of-the-art diagnostic and therapeutic infrastructure and staff expertise allows for comprehensive diagnostic work-up and treatment of admitted patients, as well as post-treatment monitoring. As a reference institution in hematology, IHT sets the national guidelines for transfusion medicine, treatment of bleeding disorders and introduces research results to clinical practice. Additional information about the Institute of Hematology and Transfusion Medicine can be found on